Metabotropic glutamate receptor 5 (GRM5) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Metabotropic Glutamate Receptor 5 (GRM5) Antibody is a Rabbit Polyclonal against GRM5.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Metabotropic Glutamate Receptor 5 (GRM5) |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Recommended Dilution | ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/100 - 1/300, IF/ICC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by affinity chromatography. |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Form | Liquid |
| Tested Applications | ELISA, WB, IHC, IF/ICC |
| Buffer | PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P41594 |
| Gene ID | 2915 |
| Alias | GRM5,GPRC1E,MGLUR5,PPP1R86,mGlu5 |
| Background | Antibody anti-GRM5 |
| Status | RUO |
| Note | Concentration: 1 mg/ml - |
Descripción
GRM5, or mGluR5, is a Group I metabotropic glutamate receptor that couples to Gq proteins, activating phospholipase C (PLC), increasing intracellular calcium levels, and triggering downstream signaling pathways such as MAPK and PI3K/Akt. GRM5 is primarily expressed in the hippocampus, cortex, and basal ganglia, where it regulates synaptic plasticity, learning, and memory formation. It also modulates long-term potentiation (LTP) and excitotoxic responses. Dysregulation of GRM5 is implicated in neurological and psychiatric disorders, including fragile X syndrome, autism spectrum disorders (ASD), schizophrenia, and addiction. GRM5 overactivation can exacerbate excitotoxicity, leading to neurodegeneration in diseases like Alzheimer’s and Parkinson’s. Antagonists of GRM5, such as selective negative allosteric modulators (NAMs), are being explored for treating neurodevelopmental disorders, anxiety, and addiction. Targeting GRM5 holds significant promise for improving synaptic function and reducing excitotoxic damage in CNS-related diseases.
Related Products
Human GRM5 (Metabotropic glutamate receptor 5)ELISA Kit
Ver Producto
Mouse Grm5(Metabotropic glutamate receptor 5) ELISA Kit
Ver Producto
Metabotropic Glutamate Receptor 5 (GRM5) Antibody
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 (also known as GPRC1E) and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. The activity of GRM5 is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system and generates a calcium-activated chloride current.
Ver Producto